Literature DB >> 10942132

Intratumoral hypericin and KTP laser therapy for transplanted squamous cell carcinoma.

P S Chung1, C K Rhee, K H Kim, W Paek, J Chung, M B Paiva, A A Eshraghi, D J Castro, R E Saxton.   

Abstract

OBJECTIVES/HYPOTHESIS: To test intratumoral photodynamic therapy (IPDT) as a new treatment for squamous cell carcinoma in a preclinical tumor model. STUDY DESIGN AND METHODS: Human P3 squamous carcinoma cells were transplanted subcutaneously in athymic nude mice and allowed to grow into 300- to 500-mm3 tumors. Hypericin dye at 1 microg/gm of body weight was injected intratumorally (IT) or intravenously (IV). After 4 hours hypericin biodistribution was assessed in ethanol extracts from tissues by fluorescence spectroscopy. IPDT also was tested by KTP laser fiberoptic insertion in tumors 4 hours after IT dye injection compared to KTP532 laser therapy alone (532 nm, 1W, 40-60 J, 0.6-mm fiber).
RESULTS: Hypericin concentration in tissues was as follows: (IT vs. IV) for tumors (3660 vs. 135 ng dye/gm tissue), lung (760 vs. 6345), liver (75 vs. 935), blood (65 vs. 480) compared to skin (465 vs. 110) or muscle (335 vs. 80) adjacent to the squamous cell tumors. Four hours after dye injection, the tumor exhibited bright orange fluorescence when excited by KTP 532-nm green laser light. The IPDT-treated tumors had a 3.32+/-0.32-mm radius of cell destruction when H&E-stained sections were examined compared with 2.5+/-0.38 mm for the laser only control group (n = 10, P = .003).
CONCLUSIONS: This pilot study indicates laser IPDT with hypericin induces a significant increase in tumor necrosis compared with laser alone and may be useful as a less invasive adjuvant treatment for recurrent or inoperable human squamous cell cancers of the head and neck.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10942132     DOI: 10.1097/00005537-200008000-00016

Source DB:  PubMed          Journal:  Laryngoscope        ISSN: 0023-852X            Impact factor:   3.325


  5 in total

1.  Hypericin-mediated photodynamic therapy of pituitary tumors: preclinical study in a GH4C1 rat tumor model.

Authors:  Chad D Cole; James K Liu; Xiaoming Sheng; Steven S Chin; Meic H Schmidt; Martin H Weiss; William T Couldwell
Journal:  J Neurooncol       Date:  2008-01-29       Impact factor: 4.130

2.  Radioiodinated hypericin: its biodistribution, necrosis avidity and therapeutic efficacy are influenced by formulation.

Authors:  Marlein Miranda Cona; Yeranddy Aguiar Alpizar; Junjie Li; Matthias Bauwens; Yuanbo Feng; Ziping Sun; Jian Zhang; Feng Chen; Karel Talavera; Peter de Witte; Alfons Verbruggen; Raymond Oyen; Yicheng Ni
Journal:  Pharm Res       Date:  2013-08-09       Impact factor: 4.200

3.  Laser light activation of a second-generation photosensitiser and its use as a potential photomodulatory agent in skin rejuvenation.

Authors:  V Van Kets; A Karsten; L M Davids
Journal:  Lasers Med Sci       Date:  2012-05-12       Impact factor: 3.161

4.  Photodynamic therapy and tumor imaging of hypericin-treated squamous cell carcinoma.

Authors:  Christian S Head; Quang Luu; Joel Sercarz; Romaine Saxton
Journal:  World J Surg Oncol       Date:  2006-12-05       Impact factor: 2.754

5.  Susceptibility of In Vitro Melanoma Skin Cancer to Photoactivated Hypericin versus Aluminium(III) Phthalocyanine Chloride Tetrasulphonate.

Authors:  I M Ndhundhuma; H Abrahamse
Journal:  Biomed Res Int       Date:  2017-09-25       Impact factor: 3.411

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.